Zobrazeno 1 - 10 of 296 pro vyhledávání: '"Paul E, Sax"'
1
Akademický článek
Coronary Microcirculatory Dysfunction in People With HIV and Its Association With Antiretroviral Therapy
Autor: Daniel M. Huck, Brittany Weber, Sean Parks, Sanjay Divakaran, Jenifer M. Brown, Courtney F. Bibbo, Leanne Barrett, Jon Hainer, Camden Bay, Laurel Martell, Laura Kogelman, Virginia A. Triant, Jacqueline Chu, Nina H. Lin, Kathleen Melbourne, Paul E. Sax, Marcelo F. Di Carli
Publikováno v: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 12, Iss 22 (2023)
Background HIV infection and abacavir‐containing antiretroviral regimens are associated with vascular endothelial dysfunction and increased cardiovascular risk. Positron emission tomography (PET)‐derived myocardial blood flow reserve (MBFR), the
Externí odkaz: https://doaj.org/article/4cf953f902d948639c647e9b723daacc
Zobrazit plný text záznamu
2
Akademický článek
Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trialsResearch in context
Autor: Paul E. Sax, José R. Arribas, Chloe Orkin, Adriano Lazzarin, Anton Pozniak, Edwin DeJesus, Franco Maggiolo, Hans-Jürgen Stellbrink, Yazdan Yazdanpanah, Rima Acosta, Hailin Huang, Jason T. Hindman, Hal Martin, Jared M. Baeten, David Wohl
Publikováno v: EClinicalMedicine, Vol 59, Iss , Pp 101991- (2023)
Summary: Background: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a single-tablet regimen recommended for HIV-1 treatment. The safety and efficacy of B/F/TAF as initial therapy was established in two Phase 3 studies: 1489 (vs dolutegr
Externí odkaz: https://doaj.org/article/3763c296832847b0809740fb61aeb872
Zobrazit plný text záznamu
3
Akademický článek
Immune-profiling of ZIKV-infected patients identifies a distinct function of plasmacytoid dendritic cells for immune cross-regulation
Autor: Xiaoming Sun, Stephane Hua, Ce Gao, Jane E. Blackmer, Zhengyu Ouyang, Kevin Ard, Andrea Ciaranello, Sigal Yawetz, Paul E. Sax, Eric S. Rosenberg, Mathias Lichterfeld, Xu G. Yu
Publikováno v: Nature Communications, Vol 11, Iss 1, Pp 1-13 (2020)
Zika virus (ZIKV) poses a significant public health threat, but the immune landscape changes following ZIKV infection is still unclear. Here, the authors show, using flow cytometry and transcriptomic data, that ZIKV induces a multitude of immune resp
Externí odkaz: https://doaj.org/article/22635906b94d4ef385dfa69cc1d812bc
Zobrazit plný text záznamu
4
Call to Action: Prioritizing the Use of Inclusive, Nonstigmatizing Language in Scientific Communications
Autor: Sara H Bares, Jasmine R Marcelin, Jill Blumenthal, Paul E Sax
Publikováno v: Clinical Infectious Diseases. 76:1860-1863
The language we use in our scientific communications can either empower or stigmatize the people we study and care for. Clinical Infectious Diseases is committed to prioritizing the use of inclusive, nonstigmatizing language in published manuscripts.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::be211f2307d410d04f55685fbc592fc5
https://doi.org/10.1093/cid/ciad055
Zobrazit plný text záznamu
5
Akademický článek
Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV.
Autor: Sonia Vibhakar Patel, Dushyantha T Jayaweera, Keri N Althoff, Joseph J Eron, Janna Radtchenko, Anthony Mills, Graeme Moyle, Steven Santiago, Paul E Sax, Jason Gillman, Karam Mounzer, Richard A Elion, Gregory D Huhn
Publikováno v: PLoS ONE, Vol 15, Iss 2, p e0228847 (2020)
The advent of direct-acting antiviral (DAA) therapies has dramatically transformed HCV treatment, with most recent trials demonstrating high efficacy rates (>90%) across all genotypes and special populations, including patients with HIV/HCV coinfecti
Externí odkaz: https://doaj.org/article/3f03854a3efb4042a1a0352f586949cf
Zobrazit plný text záznamu
7
Oral Nirmatrelvir and Ritonavir in Nonhospitalized Vaccinated Patients With Coronavirus Disease 2019
Autor: Sarju Ganatra, Sourbha S Dani, Javaria Ahmad, Ashish Kumar, Jui Shah, George M Abraham, Daniel P McQuillen, Robert M Wachter, Paul E Sax
Publikováno v: Clinical Infectious Diseases. 76:563-572
Background Treatment of coronavirus disease 2019 (COVID-19) with nirmatrelvir plus ritonavir (NMV-r) in high-risk nonhospitalized unvaccinated patients reduced the risk of progression to severe disease. However, the potential benefits of NMV-r among
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b1a2c28c44c37c0d218c579e709570e4
https://doi.org/10.1093/cid/ciac673
Zobrazit plný text záznamu
8
Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial
Autor: Lameck Chinula, Lauren Ziemba, Sean Brummel, Katie McCarthy, Anne Coletti, Chelsea Krotje, Benjamin Johnston, Kevin Knowles, Sikhulile Moyo, Lynda Stranix-Chibanda, Risa Hoffman, Paul E Sax, Jeffrey Stringer, Nahida Chakhtoura, Patrick Jean-Philippe, Violet Korutaro, Haseena Cassim, Lee Fairlie, Gaerolwe Masheto, Ceejay Boyce, Lisa M Frenkel, K Rivet Amico, Lynette Purdue, Roger Shapiro, Blandina Theophil Mmbaga, Faeezah Patel, Jean van Wyk, James F Rooney, Judith S Currier, Shahin Lockman, Brookie M. Best, Cheryl D Blanchette, Renee Browning, Nagawa Jaliaah, Mark Mirochnick, William A. Murtaugh, Emmanuel Patras, Frances Whalen, Jeremiah D. Momper, Ponego L. Ponatshego, Lesedi Tirelo, Boitshepo J. Seme, Georginah O. Modise, Mpho S. Raesi, Marian E. Budu, Moakanyi Ramogodiri, Ricardo H. Oliveira, Cristina B Hofe, Thalita Fernandes de Abreu, Lorena M. Pestanha, Esaú João, Leon C. Sidi, Trevon Fuller, Maria L.S Cruz, Jorge Pinto, Flãvia Ferreira, Mãrio Correa Jr, Juliana Romeiro, Jose H. Pilotto, Luis E.B.C Fernandes, Luiz F. Moreira, Ivete M. Gomes, Shilpa Naik, Neetal Nevrekar, Vidya Mave, Aarti Kinikar, Elizea Horne, Hamisha Soma-Kasiram, Avy Violari, Sisinyana R. Mathiba, Mandisa Nyati, Gerhard Theron, Jeanne de Jager, Magdel Rossouw, Lindie Rossouw, Sherika Hanley, Alicia C. Desmond, Rosemary Gazu, Vani Govender, Amphan Chalermchockcharoenkit, Manopchai Thamkhantho, Peerawong Werarak, Supattra Rungmaitree, Jullapong Achalapong, Lukkana Sitiritkawin, Tim R. Cressey, Pra-ornsuda Sukrakanchana, Linda Aurpibul, Fuanglada Tongprasert, Chintana Khamrong, Sopida Kiattivej, Deo Wabwire, Enid Kabugo, Joel Maena, Frances Nakayiwa, Victoria Ndyanabangi, Beatrice Nagaddya, Rogers Sekabira, Justus Ashaba, Charles D. Mitchell, Adriana Drada, Grace A. Alvarez, Gwendolyn B. Scott, Mobeen Rathore, Saniyyah Mahmoudi, Adnan Shabbir, Nizar Maraqa, Patricia F. Mandima, Mercy Mutambanengwe, Suzen Maonera, Gift Chareka, Teacler Nematadzira, Vongai Chanaiwa, Taguma A. Matubu, Kevin Tamirepi, Sukunena Maturure, Tsungai Mhembere, Tichaona Vhembo, Tinashe Chidemo
Publikováno v: The Lancet HIV.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::66eb7b2db986b5be5e1b778954e2df3d
https://doi.org/10.1016/s2352-3018(23)00061-9
Zobrazit plný text záznamu
10
High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I
Autor: Paul E. Sax, Kristen Andreatta, Jean-Michel Molina, Eric S. Daar, Debbie Hagins, Rima Acosta, Michelle L. D’Antoni, Silvia Chang, Ross Martin, Hui Liu, Christiana Blair, Ian McNicholl, Joel Gallant, Sean E. Collins, Hal Martin, Kirsten L. White
Publikováno v: AIDS. 36:1511-1520
We investigated the prevalence of preexisting M184V/I and associated risk factors among clinical trial participants with suppressed HIV and evaluated the impact of M184V/I on virologic response after switching to bictegravir/emtricitabine/tenofovir a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6708a378d909f6a774c7479a369e97a4
https://doi.org/10.1097/qad.0000000000003244
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje